DOCSLIB.ORG

[1] Vaccination Update Table of Contents: 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
[1] Vaccination Update Table of Contents: 1 EYE ON THE MARKET • MICHAEL CEMBALEST • J.P. MORGAN Last updated 9/23/2021 [1] Vaccination update Table of Contents: 1. US vaccination overview ................................................................................................................................2 2. Vaccination vs infection, mortality, hospitalization and 2020 Trump voting share ............................................3 3. “A pandemic of the unvaccinated” .................................................................................................................4 4. Population shares, vaccine efficacy and the amalgamation paradox ................................................................5 5. Vaccine efficacy tracker ..................................................................................................................................6 6. Vaccination vs previous COVID infection (acquired vs natural immunity) .........................................................7 7. Vaccine risk-benefit data ................................................................................................................................8 8. Variant prevalence by country ........................................................................................................................9 9. Delta variant facts and figures ........................................................................................................................9 10. Vaccine update by country and US state ....................................................................................................... 10 11. What about new variants and the possibility of “immunity escape”? ............................................................ 13 The table outlines the approaches that vaccine companies are taking to provoke an antibody response. Vaccines train the immune system to recognize the disease-causing part of a virus so that when people are infected, their bodies are prepared to fight the virus with a combination of antibody and T-cell responses. Historically, most vaccines contained either weakened viruses or the signature proteins of the virus (Types 1, 2 and 3), but the first approved vaccines for COVID were genetic (Types 4 and 5). See Section 5 for more information. Method of provoking antibody response Drug companies Existing licensed Type to SARS-CoV-2 (bold = approved) vaccines 1 A live but weakened coronavirus that will infect cells and cause Measles, yellow fever, Codagenix Attenuated them to make viral proteins mumps, smallpox, polio 2 A "killed" coronavirus that will get recognized as foreign matter Sinovac1, SinoPharm2, Polio (dev countries) Attenuated by the immune system Covaxin3 Recombinant coronavirus proteins, produced industrially in 3 GlaxoSmithKline/Sanofi, Tetanus, pertussis, flu, outside cell cultures, which are recognized as foreign matter by Recombinant Novavax4 shingles the immune system 5 4 A different virus (human or ape adenovirus, measles, etc) that is CanSino , Genetic engineered to include genetic components coding for the SARS- Oxford/AstraZeneca6, Ebola (vector vaccines) CoV-2 spike proteins, which causes the body to produce them J&J7, Gamaleya8 5 DNA or RNA that will be taken up by cells and will cause them to Moderna, Inovio, Genetic make coronavirus proteins BioNTech/Pfizer 1: Sinovac has been approved for use in China, Hong Kong, Indonesia, Philippines, Brazil, Chile, Mexico, Turkey and several other countries 2: Sinopharm has been approved in China, UAE, Bahrain, Egypt, Hungary and Jordan and several other countries 3: Covaxin has been approved for emergency use in India, Iran, Philippines, Paraguay, Guatemala and several other countries 4: Protein vaccines are not new, but the Novavax vaccine is combined with a proprietary adjuvant which has not been approved for use before 5: CanSino has been approved for use in China, Mexico and Pakistan 6: Oxford/AstraZeneca's vaccine has been approved for use in the UK, Europe, South Africa, Brazil, Chile, and several other countries 7: J&J's vaccine has been approved for use in the US and Bahrain 8: Gamaleya's vaccine has been approved in Russia, Argentina, Venezuela, Mexico, Hungary, Iran, UAE, and several other countries Source: J.P. Morgan Asset Management. 2021. 1 INVESTMENT AND INSURANCE PRODUCTS: • NOT A DEPOSIT • NOT FDIC INSURED • NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY • NO BANK GUARANTEE • MAY LOSE VALUE EYE ON THE MARKET • MICHAEL CEMBALEST • J.P. MORGAN Coronavirus US vaccination overview Note: the CDC estimated in August that more than 1 mm people in the US had received a third shot without being registered as taking a booster shot. The result is a small overstatement of first time and full vaccination shares of the total population, and likely a small understatement of reported booster shots (shown in the third chart). US vaccination progress US % of US population 70% 300,000 4000 Unique people vaccinated Daily infections levels (LHS) 3500 60% 250,000 Fully vaccinated 3000 50% 200,000 Current hospitalizations levels (LHS) 2500 40% 150,000 Daily deaths levels (RHS) 2000 30% 1500 20% 100,000 1000 10% 50,000 500 0% 1/1 1/31 3/2 4/1 5/1 5/31 6/30 7/30 8/29 9/28 10/28 0 0 02/20 05/20 08/20 11/20 03/21 06/21 09/21 Source: OWID, JPMAM. September 22, 2021. Dotted lines indicate estimated vaccination rate based on trailing 7-day average vaccination rate. Source: JHU, IMF, HHS, JPMAM. Sep 22, 2021. 7 day smoothing. US daily vaccinations US vaccination progress Millions of people, 7-day average % of US population 3.5 70% 3.0 60% 2.5 Full 50% vaccinations 2.0 (2nd of 2 doses) 40% Unique Fully 1.5 Full people vaccinated vaccinations Booster 30% vaccinated 1.0 (1 dose) shots 20% 0.5 Partial vaccinations (1st of 2 doses) 10% Partially 0.0 1/7 1/28 2/18 3/11 4/1 4/22 5/13 6/3 6/24 7/15 8/5 8/26 9/16 0% vaccinated Source: OWID, JPMAM. September 22, 2021. Source: OWID, JPMAM. September 22, 2021. Lowest vaccination counties with more than 100,000 people 1 Shelby AL 25.6% 11 Houston AL 30.5% 21 Rowan NC 32.4% 31 Kootenai ID 33.8% 2 Robeson NC 27.1% 12 Anderson SC 30.8% 22 Tangipahoa LA 32.4% 32 Jefferson MO 33.8% 3 Livingston LA 27.8% 13 Canyon ID 30.8% 23 Randolph NC 32.5% 33 Allen OH 34.1% 4 Etowah AL 28.6% 14 Kings CA 31.0% 24 Calhoun AL 32.5% 34 Baldwin AL 34.2% 5 Harnett NC 28.7% 15 Jackson MS 31.2% 25 Ouachita LA 32.8% 35 Berkeley SC 34.3% 6 Matanuska-Susitna AK29.0% 16 Mohave AZ 31.9% 26 Flathead MT 32.9% 36 Sumter SC 34.4% 7 Calcasieu LA 29.9% 17 Tuscaloosa AL 32.0% 27 Sebastian AR 32.9% 37 Aiken SC 34.5% 8 Lee AL 29.9% 18 Morgan AL 32.1% 28 Merced CA 33.0% 38 Elkhart IN 34.5% 9 Bradley TN 30.4% 19 Spartanburg SC 32.3% 29 Bossier LA 33.2% 39 York SC 34.6% 10 Craighead AR 30.4% 20 Terrebonne LA 32.3% 30 Mobile AL 33.6% 40 Rapides LA 34.9% Source: JHU, CDC, State Health Departments, Census. September 22, 2021. 5 lowest vaccination states compared to the US average State ND MS WV WY ID USA Total population 50% 50% 48% 48% 46% 64% 18-64 population 56% 55% 49% 52% 55% 72% 18+ population 63% 61% 57% 59% 62% 76% 65+ population 86% 84% 79% 83% 86% 93% Source: OWID, CDC, JPMAM. September 22, 2021. 2 EYE ON THE MARKET • MICHAEL CEMBALEST • J.P. MORGAN Coronavirus Vaccination vs infection, mortality, hospitalization and 2020 Trump voting share US county infections vs vaccinations US county deaths vs vaccinations Cumulative infections per mm since July 2021 Cumulative deaths per mm since July 2021 100,000 1,600 90,000 1,400 80,000 1,200 70,000 1,000 60,000 50,000 800 40,000 600 30,000 400 20,000 200 10,000 0 0 0% 20% 40% 60% 80% 100% 0% 20% 40% 60% 80% 100% Average fully vaccinated people as % of state population since July 2021 Average fully vaccinated people as % of state population since July 2021 Source: JHU, CDC, State Health Departments, Census. September 22, 2021. Source: JHU, CDC, State Health Departments, Census. September 22, 2021. US state hospitalizations vs vaccinations Trump share of 2020 vote and vaccination by county Average hospitalization rate per mm since July 2021 Fully vaccinated people as a % of county population 600 90% R² = 0.40 80% 500 FL 70% 400 AL 60% MS GA ARLA NV TX KY 50% 300 TN MO OK SC 40% WV WY NCIN AZ 200 ID KS 30% MT HI AKOH OR DE WA CA ND NEIA DC NM UT SD IL VA 20% 100 WIPA CO MD NYNJ RI MI MN CTME NH MA 10% VT 0 0% 30% 40% 50% 60% 70% 0% 20% 40% 60% 80% 100% Average fully vaccinated people as % of state population since July 2021 % of county population who voted for Trump Source: OWID, HHS, IMF, JPMAM. September 22, 2021. Source: Harvard Dataverse, CDC, State Health Depts, JPMAM. September 22, 2021. 3 EYE ON THE MARKET • MICHAEL CEMBALEST • J.P. MORGAN Coronavirus “A pandemic of the unvaccinated” Note: Given higher vaccination rates among older age groups as well as higher probabilities of hospitalization once infected with COVID, it is important to pay attention to age-stratified infection and hospitalization rates when comparing vaccination status, as Seattle/King County has reported in the charts below. The following page goes into more detail on the importance of age-adjusting COVID data. Seattle: age adjusted infections Seattle: age adjusted hospitalizations Daily infections, # per mm, smoothing = 7 days Current hospitalizations, # per mm, smoothing = 7 days 120 1,000 Not fully vaccinated Not fully vaccinated 900 Overall Overall 100 800 Fully vaccinated Fully vaccinated 700 80 600 500 60 400 40 300 200 20 100 0 0 Jan '21 Mar '21 May '21 Jul '21 Sep '21 Jan '21 Mar '21 May '21 Jul '21 Sep '21 Source: Washington Department of Health. September 8, 2021. Source: Washington Department of Health. September 8, 2021. The below table shows the multiple of hospitalization and death risk for unvaccinated people compared to vaccinated people. The rates are population-adjusted and reflect state estimates of breakthrough hospitalizations and deaths since vaccination began in January 2021. The table reports data on states who provided at least two months of records to the New York Times.
Load more

Recommended publications
  • Snapshot of Notable Global COO, CIO and CISO Moves and Appointments
    Snapshot of notable global COO, CIO and CISO moves and appointments September 2016 For the latest EMEA, Americas and Asia Pacific moves across: Analytics Data Corporate Services Cyber-Security Facilities Operations Procurement Technology Vendor Management Snapshot of notable global Operations and Technology moves and appointments Page 1 / 6 Next update due: January 2017 People Moves FS EMEA John Burns, the former CTO of Pioneer Investments, joins Cyril Reol, former Glencore CIO, has joined Man Group Deutsche Bank as Global CIO, COO Asset Management as Deputy CTO. Garry Beaton, former Global Head of Operations at Core Technology . Andrew Brown, former Barclays UK Private Bank Chief of Ashmore, joins the Abu Dhabi Investment Authority as its Tom Waite, joins Deutsche Bank as an MD within Staff, has joined US Expat and Fatca Specialist Maseco Global Head of Operations. electronic trading. Waite joined from Bank of America, Private Wealth as its COO. Lesley Cairney has joined Artemis Investment where he was also an MD. Before that, he was an MD at Ken Moore, former Head of Citi Innovation Labs, joins Management as COO. She was formerly at Henderson Goldman Sachs for six years until May 2014. MasterCard as EVP Labs, running global innovation. Global Investors as COO. Amish Popat joins Dromeus Capital Group as COO from David Grant has joined Nationwide as Head of IT and Lewis Love, the former Global Chief Procurement Officer New Amsterdam Capital, where he was the Finance and Security Risk from Lloyds Banking Group, where he was for Aon has been named as the COO for Bank of Ireland, Operations Manager.
    [Show full text]
  • Eli 022807Me
    ORANGE COUNTY TREASURER-TAX COLLECTOR APPROVED ISSUER LIST COMMERCIAL PAPER / MEDIUM TERM NOTES AS OF: 2/28/2007 CR S/T RATINGS L/T RATINGS PROG RATINGS IND. ISSUER (Shared Structure) # S&P MDY FI S&P MDY FI S&P MDY FI PARENT/ ADMINISTRATOR CODE ADP TAX SERVICES INC 1 A-1+ P-1 NR AAA Aaa NR A-1+ P-1 NR AUTO DATA PROCES 9.4 ALCON CAPITAL CORP 1 A-1+ P-1 NR NR NR NR A-1+ P-1 F1+ NESTLE SA 4.7 AMERICAN HONDA FINANCE 9 A-1 P-1 F1 A+ A1 *+ NR A-1 P-1 F1 AMER HONDA MOTOR 3.3 AMSTERDAM FUNDING CORP 7 NR NR NR NR NR NR A-1 P-1 NR ABN AMRO Bank N.V 7.4 AB AUTOMATIC DATA PROCESSNG 1 A-1+ P-1 NR AAA Aaa NR A-1+ P-1 NR AUTOMATIC DATA PROCESSING, INC. 9.4 AQUINAS FUNDING LLC 3 NR NR NR NR NR NR A-1+ P-1 NR RABOBANK NEDERLAND 7.4 AB ASPEN FUND (w/ Newport Fund) 3 NR NR NR NR NR NR A-1+ P-1 F1+ DEUTSCHE BANK AG 7.4 AB BANK OF AMERICA CORP 5 A-1+ P-1 F1+ AA Aa2 AA A-1+ P-1 F1+ DOMESTIC BANK/FDIC INSURED 7.1 BARCLAYS US FUNDING LLC 4 A-1+ P-1 F1+ AA Aa1 AA+ A-1+ P-1 NR BARCLAYS BK PLC 7.4 BARTON CAPITAL LLC 3 NR NR NR NR NR NR A-1+ P-1 NR SOC GENERALE 7.4 AB BEETHOVEN FUNDING CORP 7 NR NR NR NR NR NR A-1 P-1 NR DRESDNER BANK, AG 7.4 AB BETA FINANCE INC 1 A-1+ P-1 F1+ AAA Aaa AAA A-1+ P-1 F1+ 7.4 AB BMW US CAPITAL LLC 9 A-1 P-1 NR NR A1 NR A-1 P-1 NR BMW AG 3.3 BNP PARIBAS FINANCE INC 5 A-1+ P-1 F1+ AA Aa2 NR A-1+ P-1 NR BNP PARIBAS 7.4 BRYANT PARK FUNDING LLC 7 NR NR NR NR NR NR A-1 P-1 NR HSBC 7.4 AB CALYON NORTH AMERICA INC 6 A-1+ P-1 F1+ AA- Aa2 AA A-1+ P-1 F1+ CALYON 7.1 CATERPILLAR FIN SERV CRP 10 A-1 P-1 F1 A A2 A+ A-1 P-1 F1 CATERPILLAR INC 8.8 CATERPILLAR INC 10 A-1 P-1 F1 A A2 A+ A A2 A+ #N/A N Ap 8.8 CC USA INC 1 A-1+ P-1 NR AAA Aaa NR AAA Aaa NR SECURITY TRUST 7.4 AB CHARIOT FUNDING LLC 7 NR NR NR NR NR NR A-1 P-1 NR JP MORGAN CHASE 7.4 AB CIT GROUP INC 10 A-1 P-1 F1 A A1 A A-1 P-1 F1 #N/A N Ap 7.4 CITIGROUP FUNDING INC 4 A-1+ P-1 F1+ AA Aa1 AA+ A-1+ P-1 F1+ FORMERLY TRAVELERS GROUP INC.
    [Show full text]
  • Polio Vaccine Safety Paul Meier's Role in the Discovery And
    www.barkerstats.com Polio Vaccine the cutter incident October 1, 2020 Downloaded from www.barkerstats.com/PDFs/Meier/Meier-Cutter-Incident-History.pdf Polio Vaccine Safety Paul Meier’s Role in the Discovery and Evaluation of The Cutter Incident Professor Chris Barker, Ph.D. Adjunct Associate Professor of Biostatistics, UIC SPH. www.barkerstats.com Page 1 of 11 www.barkerstats.com Polio Vaccine the cutter incident October 1, 2020 Contents Background .................................................................................................................................................................................................................... 3 Brief Polio Vaccine Overview ......................................................................................................................................................................................... 3 Polio Vaccine Manufacturing Data Suppression ............................................................................................................................................................ 4 Biological Disaster? How Serious was the vaccine manufacturing problem? ............................................................................................................... 5 Near Elimination of Vaccine development by lawsuits ................................................................................................................................................. 6 Meier’s evaluation of the safety recommendations following The Cutter Incident ....................................................................................................
    [Show full text]
  • Cohen & Steers Preferred Securities and Income Fund
    Cohen & Steers Preferred Securities and Income Fund As of 06/30/2021 Current % of Total Security Name Sector Market Value Market Value Wells Fargo & Company Flt Perp Banking $219,779,776.15 1.81 % Charles Schwab Corp Flt Perp Sr:I Banking $182,681,675.00 1.51 % Bp Capital Markets Plc Flt Perp Energy $158,976,029.00 1.31 % Bank of America 6.25% Banking $148,052,279.38 1.22 % Bank of Amrica 6.10% Banking $144,075,863.52 1.19 % Citigroup Inc Flt Perp Banking $139,736,756.25 1.15 % Emera 6.75% 6/15/76-26 Utilities $134,370,096.24 1.11 % Transcanada Trust 5.875 08/15/76 Pipeline $116,560,837.50 0.96 % JP Morgan 6.75% Banking $116,417,211.75 0.96 % JP Morgan 6.1% Banking $115,050,549.38 0.95 % Credit Suisse Group AG 7.5 Perp Banking $112,489,090.00 0.93 % Enbridge Inc Flt 07/15/80 Sr:20-A Pipeline $101,838,892.50 0.84 % Charles Schwab Corp Flt Perp Sr:G Banking $101,715,980.40 0.84 % Bank of America Corp 5.875% Perp Banking $99,269,540.97 0.82 % Sempra Energy Flt Perp Utilities $97,680,337.50 0.81 % BNP Paribas 7.375% Banking $96,328,288.48 0.79 % Jpmorgan Chase & Co Flt Perp Sr:Kk Banking $95,672,863.00 0.79 % Metlife Capital Trust IV 7.875% Insurance $94,971,600.00 0.78 % Citigroup 5.95% 2025 Call Banking $89,482,599.30 0.74 % Transcanada Trust Flt 09/15/79 Pipeline $88,170,468.75 0.73 % Ally Financial Inc Flt Perp Sr:C Banking $86,422,336.00 0.71 % Banco Santander SA 4.75% Flt Perp Banking $83,189,000.00 0.69 % American Intl Group 8.175% 5/15/58 Insurance $82,027,104.20 0.68 % Prudential Financial 5.625% 6/15/43 Insurance $80,745,314.60 0.67
    [Show full text]
  • JPMS CWM Trading Away Disclosure
    Important Information about Portfolio Managers Trading Away in J.P. Morgan Securities LLC ("JPMS") Wrap Fee Investment Advisory Programs JPMS offers certain wrap-fee investment advisory programs that provide discretionary portfolio management of client assets by affiliated or unaffiliated Portfolio Managers (collectively referred to as “Wrap Fee Programs”). In the Chase Investments division of JPMS, the following Wrap Fee Programs are offered: Chase Strategic Portfolio (“CSP”) Program, J.P. Morgan Core Advisory Portfolio (“JPMCAP”) Program, the Fixed Income Advisory Program, and the Advisory Program. In the J.P. Morgan Securities division of JPMS, the following Wrap Fee Programs are offered: the Strategic Investment Services (“STRATIS”) Program; Investment Counseling Service (“ICS”) Program; Unified Managed Account (“UMA”) Program; Customized Bond Solutions (“C-BoS”) Program; and JPMCAP Program This document provides information to clients, who are participating, or are considering participating, in a Wrap Fee Program, about Portfolio Managers’ placement of client trade orders for execution by broker- dealers other than JPMS. This practice is frequently referred to as “trading away.” The extent to which a Portfolio Manager chooses to trade away from JPMS can affect your total cost of investing in a Wrap Fee Program. When a Portfolio Manager places trades with JPMS for execution in a Wrap Fee Program, your account does not incur any additional costs because trade execution by JPMS is covered by the wrap fee you pay to JPMS. However, when a Portfolio Manager chooses to trade away from JPMS, execution by a broker-dealer other than JPMS is not covered by the wrap fee you pay to JPMS and your account therefore may incur a commission or other additional cost.
    [Show full text]
  • Bank of America Corporation Amicus Brief
    Nos. 19-675 & 19-688 IN THE BANK OF AMERICA CORPORATION, et al., Petitioners, v. CITY OF MIAMI, FLORIDA, Respondent. WELLS FARGO & CO., et al., Petitioners, v. CITY OF MIAMI, FLORIDA, Respondent. On Petitions for Writs of Certiorari to the United States Court of Appeals for t he Eleventh Circuit BRIEF OF THE AMERICAN BANKERS ASSOCIATION, AMERICAN FINANCIAL SERVICES ASSOCIATION, BANK POLICY INSTITUTE, CONSUMER BANKERS ASSOCIATION, INDEPENDENT COMMUNITY BANKERS OF AMERICA, MORTGAGE BANKERS ASSOCIATION, CREDIT UNION NATIONAL ASSOCIATION AND NATIONAL ASSOCIATION OF FEDERALLY-INSURED CREDIT UNIONS AS AMICI CURIAE S UPPORT ING PETITIONERS Robert A. Long, Jr. Counsel of Record Jordan V. Hill COVINGTON & BURLING LLP One CityCenter 850 Tenth Street, N.W. Washington, DC 20001-4956 [email protected] (202) 662-6000 Counsel for Amici Curiae TABLE OF CONTENTS Page TABLE OF AUTHORITIES ....................................... ii INTEREST OF AMICI CURIAE ............................... 1 SUMMARY OF ARGUMENT .................................... 4 ARGUMENT .............................................................. 7 I. This Case Presents an Issue of Exceptional Importance That Warrants This Court’s Review. ........................................ 7 II. The Court of Appeals Failed to Heed This Court’s Decision. ............................................ 10 III. Other Plaintiffs Are Well-Positioned to Enforce the FHA ............................................ 13 CONCLUSION ......................................................... 17 i ii TABLE OF AUTHORITIES Page(s) Cases Associated Gen. Contractors of Cal., Inc. v. Carpenters, 459 U.S. 519 (1983) ................................ 6 Bank of America v. City of Miami, Florida, 137 S. Ct. 1296 (2017) ..................................... passim City of Miami Gardens, v. Bank of America Corp., No. 1:14-cv-22202 (S.D. Fla., filed June 13, 2014) ............................................................ 7 City of Miami Gardens v. Citigroup, Inc., No. 1:14-cv-22204 (S.D.
    [Show full text]
  • 2Q21 Earnings Press Release
    JPMorgan Chase & Co. 383 Madison Avenue, New York, NY 10179-0001 NYSE symbol: JPM www.jpmorganchase.com JPMORGAN CHASE REPORTS SECOND-QUARTER 2021 NET INCOME OF $11.9 BILLION ($3.78 PER SHARE) SECOND-QUARTER 2021 RESULTS1 ROE 18% CET1 Capital Ratios3 Net payout LTM4,5 ROTCE2 23% Std. 13.0% | Adv. 13.8% 45% n Reported revenue of $30.5 billion; managed revenue Jamie Dimon, Chairman and CEO, commented on the financial results: “JPMorgan of $31.4 billion2 Chase delivered solid performance across our businesses as we generated over $30 billion in revenue while continuing to make significant investments in technology, Credit costs net benefit of $2.3 billion included $3.0 people and market expansion. This quarter we once again benefited from a significant n reserve release as the environment continues to improve, but as we have said before, we Firmwide billion of net reserve releases and $734 million of net do not consider these core or recurring profits. Our earnings, not including the reserve Metrics charge-offs release, were $9.6 billion. Consumer and wholesale balance sheets remain 6 exceptionally strong as the economic outlook continues to improve. In particular, net n Average loans flat; average deposits up 23% charge-offs, down 53%, were better than expected, reflecting the increasingly healthy condition of our customers and clients.” $1.6 trillion of liquidity sources, including HQLA and n 7 unencumbered marketable securities Dimon continued: “In Consumer & Community Banking, combined debit and credit card spend was up 45%, or up 22% versus the more normal, pre-pandemic second n Average deposits up 25%; client investment assets up quarter of 2019.
    [Show full text]
  • Our Global Initiative
    2021 OUR GLOBAL INITIATIVE AN ASSESSMENT OF COVID-19 & THE FAILED GLOBAL HEALTH POLICIES OF THE WHO OUR GLOBAL INITIATIVE In early 2020, Australia, and indeed the world, collapsed into a lockdown prompted by the World Health Organisation in its designation of Covid 19 as a pandemic. What began as “2 weeks to flatten the curve” quickly morphed into a year of intermittent lockdowns, a loss of freedoms and liberties, the decimations of SME’s, irrational restrictions, unadulterated government surveillance, an endless state of emergencies, the rise of the police state a totalitarian grand stride towards medical fascism and a technocratic dictatorship as well as the end of civil society as we know it. What happened? How did we get here? Where are we going? What does this world of the “New Normal” hold for not only Australia, but the human civilisation? How do we navigate this reality and not only survive but thrive? The Global Health Organisation, in collaboration with the Australian Patriots Alliance, the World Solutions Foundation, the QuantumPrism Foundation, Ikighais Pty Ltd and other concerned institutions (the Initiative) have commissioned this report in effort to gain an insight into what is going on; the why, they how and the WHO! Further, the report will offer solutions to current concerns, as well as ways for interested parties to position themselves to thrive and win in the new society bound to emerge from the ashes of this dying world. 2 TIPS TO HELP READ THIS REPORT This report contains a lot of information and we appreciate SUMMARY POINTS that time is scarce.
    [Show full text]
  • JP Morgan Investment Management Inc. | Client Relationship Summary
    J.P. MORGAN INVESTMENT MANAGEMENT INC. JULY 9, 2021 Client Relationship Summary The best relationships are built on trust and transparency. That’s why, at J.P. Morgan Investment Management Inc. (“JPMIM”, “our”, “we”, or “us”), we want you to fully understand the ways you can invest with us. This Form CRS gives you important information about our wrap fee programs, short-term fixed income and private equity separately managed accounts (“SMAs”). We are registered with the Securities and Exchange Commission (“SEC”) as an investment adviser. Brokerage and investment advisory services and fees differ, and it is important for retail investors (“you”) to understand the differences. Free and simple tools are available for you to research firms and financial professionals at Investor.gov/CRS, which also provides educational materials about broker-dealers, investment advisers, and investing. WHAT INVESTMENT SERVICES AND ADVICE CAN YOU PROVIDE ME? We have minimum account requirements, and for Private Equity SMAs, Wrap Fee and Other Similar Managed Account Programs clients must generally satisfy certain investor sophistication requirements. We offer investment advisory services to retail investors through SMAs More detailed information about our services is available at available within wrap fee and other similar managed account programs. www.jpmorgan.com/form-crs-adv. These programs are offered by certain financial institutions, including our affiliates ("Sponsors"). Depending on the SMA strategy, these accounts invest in individual securities (such as stocks and bonds), exchange-traded funds CONVERSATION STARTERS (“ETFs”) and/or mutual funds. Throughout this Client Relationship Summary we’ve included When we act as your discretionary investment manager, you give us “Conversation Starters.” These are questions that the SEC thinks you authority to make investment and trading decisions for your account without should consider asking your financial professional.
    [Show full text]
  • Standard Settlement Instructions
    STANDARD SETTLEMENT INSTRUCTIONS For Account of: Bank Leumi (UK) PLC SWIFT: LUMIGB22WES Further Credit to: Your beneficiary account name & number in full AUD - AUSTRALIAN DOLLAR Pay to Bank: JPMorgan Chase Bank, N.A. London SWIFT: CHASGB2LXXX Cover Through: Australia and New Zealand Banking Group SWIFT: ANZBAU3MXXX CAD – CANADIAN DOLLAR Pay to Bank: JPMorgan Chase Bank, N.A. London SWIFT: CHASGB2LXXX Cover Through: Royal Bank of Canada, Toronto SWIFT: ROYCCAT2XXX CHF – SWISS FRANC Pay to Bank: JPMorgan Chase Bank, N.A. London SWIFT: CHASGB2LXXX Cover Through: UBS Switzerland AG, Zurich SWIFT: UBSWCHZH80A CNY - CHINESE YUAN RENMINBI Pay to Bank: Hongkong & Shanghai Banking, Hong Kong SWIFT: HSBCHKHHHKH CZK – CZECH KORUNA Pay to Bank: JPMorgan Chase Bank, N.A. London SWIFT: CHASGB2LXXX Cover Through: Ceskoslovenska Obchodni Banka AS, Prague SWIFT: CEKOCZPPXXX DKK – DANISH KRONE Pay to Bank: JPMorgan Chase Bank, N.A. London SWIFT: CHASGB2LXXX EUR – EURO Pay to Bank: J.P. Morgan AG. Frankfurt SWIFT: CHASDEFXXXX EUR – EURO Pay to Bank: J.P. Morgan AG. Frankfurt SWIFT: CHASDEFXXXX 1 STANDARD SETTLEMENT INSTRUCTIONS For Account of: Bank Leumi (UK) PLC SWIFT: LUMIGB22WES Further Credit to: Your beneficiary account name & number in full GBP – STERLING (CHAPS / UK SETTLEMENTS) Sort Code: 30-14-95 GBP – STERLING (INTERNATIONAL) Pay to Bank: HSBC, London SWIFT: MIDLGB22XXX HKD – HONG KONG DOLLAR Pay to Bank: JPMorgan Chase Bank, N.A. London SWIFT: CHASGB2LXXX Cover Through: JPMorgan Chase Bank, Hong Kong Branch SWIFT: CHASHKHHXXX HUF – HUNGARIAN FORINT Pay to Bank: JPMorgan Chase Bank, N.A. London SWIFT: CHASGB2LXXX Cover Through: UniCredit Bank Hungary SWIFT: BACXHUHBXXX ILS – ISRAELI SHEKEL Pay to Bank: Bank Leumi Le-Israel BM, Tel Aviv SWIFT: LUMIILITXXX JPY – JAPANESE YEN Pay to Bank: JPMorgan Chase Bank, N.A.
    [Show full text]
  • XS2075811948 Final Terms
    S&S DRAFT: 29 OCTOBER 2019 FINAL TERMS PROHIBITION OF SALES TO EEA RETAIL INVESTORS – The Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the European Economic Area (“EEA”). For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MiFID II”); or (ii) a customer within the meaning of Directive 2016/97/EU (as amended or superseded, the “Insurance Distribution Directive”), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II. Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the “PRIIPs Regulation”) for offering or selling the Notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the Notes or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation. MIFID II PRODUCT GOVERNANCE / PROFESSIONAL INVESTORS AND ECPS ONLY TARGET MARKET: SOLELY FOR THE PURPOSES OF THE MANUFACTURER’S PRODUCT APPROVAL PROCESS, THE TARGET MARKET ASSESSMENT IN RESPECT OF THE NOTES HAS LED TO THE CONCLUSION THAT: (A) THE TARGET MARKET FOR THE NOTES IS ELIGIBLE COUNTERPARTIES AND PROFESSIONAL CLIENTS ONLY, EACH AS DEFINED IN DIRECTIVE 2014/65/EU (AS AMENDED, “MIFID II”); AND (B) ALL CHANNELS FOR DISTRIBUTION OF THE NOTES TO ELIGIBLE COUNTERPARTIES AND PROFESSIONAL CLIENTS ARE APPROPRIATE.
    [Show full text]
  • Settlement Banks for FX and MM Transactions, Options and Derivatives
    Settlement Banks for FX and MM Transactions, Options and Derivatives Cou ntry: Currency: Correspondent Bank: SWIFT: Australia AUD National Australia Bank Ltd., Me lbourne NATAAU33033 Acc. 1803012548500 Bulgaria BGN Unicredit Bulbank AD, Sofia UNCRBGSF IBAN BG42UNCR96601030696607 Canada CAD Royal Bank of Canada, Toronto ROYCCAT2 Acc. 095912454619 SYDBANK A/S China CNY Standard Chartered Bank Ltd., Hong Kong SCBLHKHH Acc. 44709448980 Czech R epublic CZK Unicredit Bank Czech Republic AS , Prague BACXCZPP IBAN: CZ242700000000008166802 8 Acc. 81668028 Denmark DKK Danmarks Nationa lbank, Copenhagen DKNBDKKK Acc. 1115 -4 IBAN DK0910050000011154 Euroland EUR Commerzbank A G, Frankfurt COBADEFF Acc. 4008724346 IBAN DE 83500400000872434600 Hong Kong HKD Stan dard Chartered, Hong Kong SCBLHKHH Acc. 44708122739 Hungary HUF OTP Bank PLC , Budapest OTPVHUHB IBAN: HU66117820078102030800000000 Iceland ISK NBI HF NBIIISRE IBAN: IS230100270912726805925439 India INR Standard Chartered Bank , New Delhi SCBLINBB Acc. 222 -0-523804 -8 Indonesia IDR Standard Chartered Bank, Jakarta SCBLIDJX Japan JPY Bank of Tokyo -Mitsubishi UFJ Ltd , Tokyo BOTKJPJT Acc. 653 -0440973 Kenya KES Kenya Commercial Bank, Nairobi KCBLKENX Mexico MXN BBVA Bancomer S.A., Mexico BCMRMXMMCOR Acc. 0095001475 Morocco MAD Banque Marocaine du Commerce Extérieur, Cass ablanca BMCEMAMC New Ze aland NZD ANZ National Bank Ltd , Wellin gton ANZBNZ22058 Acc. 266650 -00001 NZD NO.1 Nor way NOK DNB Nor Bank ASA , Oslo DNBANOKK IBAN: NO32 70010213124 Acc. 7001.02.13124 Valid from: 24.02.2021 Sydbank A/S, CVR No DK 12626509, Aabenraa www.sydbank.com Page: 1/2 Settlement Banks for FX and MM Transactions, Options and Derivatives Cou ntry: Currency: Correspondent Bank: SWIFT: Poland PLN Bank Millennium SA, Warsaw BIGBPLPW IBAN PL 02116022020000000039897935 Romania RO N UniCredit Tiriac Bank SA, Bucharest BACXROBU IBAN RO65B ACX0000000001413310 Saudi Arabia SAR Saudi British Bank, Riyadh SABBSARI Acc.
    [Show full text]